Yonsei University

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

638

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

27 drugs in development

Approved1

Phase 35

Phase 214

Preclinical11

By Therapeutic Area

top 6

Oncology

1134%

Cardiovascular

516%

Metabolic & Endocrine

26%

Infectious Disease

13%

Neurology

13%

Nephrology

13%

R&D Momentum

85/100

Pipeline Velocity

60/100

Trial Completion Rate

92/100

Pipeline Concentration

25/100

Pipeline Freshness

32/100

Strategic Signals

↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 18, 2026

Recruiting

Prognostic Significance of Multi-site Pulse Oximetry Differences in Dyspneic Emergency Department Patients

Sep 11, 2026

Active, not recruiting

VEnous cLOsure vs. FIgRE of 8 Suture After AF Ablation: The VELOFIRE Randomized Trial

Earlier

Sep 5, 2026TrialLurbinectedin in Combination With Paclitaxel Versus Paclitaxel for Patients With Previously Treated Small Cell Lung Cancer: Randomized, Phase II, Open-label, Multi-center, Prospective Trial(LUPINE)

Sep 5, 2026TrialProspective Evaluation of Artificial Intelligence-generated History of Present Illness Drafts in the Emergency Department

Sep 5, 2026TrialAppropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents (ADAPT AF-DES)

Sep 5, 2026TrialCOMparisons of Different Procedural endPoints in pAtients Who undeRgo Left Bundle Branch arEa Pacing: Direct Capture of Left Ventricular Conduction SYstem Versus Left veNtricular Septal Capture (COMPARE-SYNC): A Multicenter, Prospective, Randomized Controlled Study

Sep 3, 2026TrialA Phase 1, Investigator-Initiated, Open-Label, Dose-Escalation Study to Evaluate the Safety, MTD, and Antitumor Activity of JIN-A02 in Combination With Amivantamab in EGFR-Mutant NSCLC Patients Following 3rd-Generation EGFR-TKI Failure

Aug 27, 2026TrialMulti-center, Open-label, Single-arm Phase II Clinical Trial of Sacituzumab-Govitecan Plus Q901 in Advanced TNBC

1 more events

Aug 25, 2026TrialA Phase 2, Open-label Trial of Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(5 drugs)

—

Cardiovascular(5 drugs)

Infectious Disease(1 drug)

—

Infectious Disease(1 drug)

Metabolic & Endocrine(2 drugs)

—

Metabolic & Endocrine(2 drugs)

Nephrology(1 drug)

—

Nephrology(1 drug)

Neurology(1 drug)

—

Neurology(1 drug)

Oncology(11 drugs)

—

Oncology(11 drugs)

Respiratory(1 drug)

—

Respiratory(1 drug)

Unknown / Other(10 drugs)

—

Unknown / Other(10 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)